ASCO Genitourinary Cancers Symposium


 

ASCO GU 2022 PROpel Phase III Trial Highlights: Olaparib & Abiraterone vs. Placebo & Abiraterone as 1L Therapy for mCRPC

364 views
March 8, 2022
0 Comments
Login to view comments. Click here to Login